Two More Pairs of Denosumab Biosimilars Enter US Market

Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone

November 18th 2023

By Deana Ferreri, PhD

A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.

The Top 5 Biosimilar Articles for the Week of November 13

November 17th 2023

By Skylar Jeremias

Here are the top 5 biosimilar articles for the week of November 13, 2023.

Webinar: Where Do Biosimilars Fit Into the Cancer Treatment Puzzle?

November 16th 2023

In partnership with The Center for Biosimilars®, the International Generic and Biosimilar Association hosted a live webinar, where panelists gathered from around the globe to discuss benefits as well as major barriers and accessibility challenges associated with oncology biosimilars worldwide.

Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe

November 16th 2023

By Skylar Jeremias

In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.

Part 2: French Study Finds Trastuzumab Biosimilar Program Could Generate Meaningful Savings

November 15th 2023

By Skylar Jeremias

In part 2 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® explores a cost-effectiveness analysis evaluating the use of subcutaneous trastuzumab biosimilars to treat breast cancer in a French hospital setting.

Switching Patients from Reference Product to Biosimilar

November 14th 2023

Insight surrounding the switch from reference drugs to biosimilars is provided by Bincy Abraham, MD, MS.

Initiating Biosimilar Treatment in Patients Without Previous Reference Biologic Experience

November 14th 2023

Vibeke Strand, MD, evaluates implementation of biosimilars in patients with no history of reference biologic use.

Part 1: Oncology Biosimilars Offer Comparable Benefits to Originators at Lower Prices

November 14th 2023

By Skylar Jeremias

In part 1 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® looks at a retrospective study comparing the clinical benefits, price changes, and uptake associated with oncology biosimilars in China.

Panelists Deliberate Strategies to Enhance Biosimilar Integration in Managed Care Spaces

November 13th 2023

By Skylar Jeremias

At the recent Academy of Managed Care Pharmacy Nexus meeting, panelists discussed the impact of introducing biosimilars in new medical fields, emphasizing the need for more education and collaboration to ensure their smooth integration into health care systems.

Dr Ryan Haumschild Draws Link Between Biosimilars, Health Equity in Breast Cancer

November 12th 2023

By Skylar Jeremias

Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, discusses the growth and continued challenges facing biosimilars used to treat breast cancer.